Table 2 Characteristics of the five trials selected showing general intervention information
Study | Combine | IA | IV | Transfusion criteria | Pneumatic tourniquet | Thromboprophylaxis | DVT screening method | |
|---|---|---|---|---|---|---|---|---|
IA | IV | |||||||
Huang ZY | 1.5 g TXA 50 mL NS after implantation of the components | 1.5 g TXA before inflation of the tourniquet | 3 g TXA before inflation of the tourniquet | 7.0 g/dL < HB < 10 g/dL + symptomatic anemia HB < 7.0 g/dL | Yes | LMWH | Doppler ultrasound | |
Jain NP | 2 g TXA 30 mL NS 5 min before closure of arthrotomy | 15 mg/kg TXA 30 min before skin incision 10 mg/kg TXA 3 and 6 h after surgery | 15 mg/kg TXA 30 min before skin incision 10 mg/kg TXA 3 and 6 h after surgery | 7.0 g/dL < HB < 8.0 g/dL + symptoms HB < 7.0 g/dL | No | Aspirin | Ultrasonographic + clinical symptom | |
Lin SY | 1 g TXA after joint capsule closure | 1 g TXA 15 min before skin incision | 1 g TXA 20 mL NS after joint capsule closure | HB < 8.0 g/dL HB < 9.0 g/dL +symptoms | Yes | Rivaroxaban | Clinical symptom | |
Nielsen CS | 3 g TXA 100 mL NS after closure of the capsule | 1 g TXA preoperative | 1 g of TXA | HB < 7.5 g/dL HB < 10 g/dL +symptoms postoperative Hb level was reduced >25% + symptoms | No | Rivaroxaban | NS | |
Song EK | 1.5 g TXA 50 mL NS after wound close | 10 mg/kg 20 min before tourniquet application 10 mg/kg 3 h after the second dose | 1.5 g TXA 50 mL NS after wound closure | 10 mg/kg 20 min before tourniquet application 10 mg/kg 15 min before deflation of the tourniquet 10 mg/kg 3 h after the second dose | HB < 8 g/dL | Yes | LMWH | Clinical symptom + Doppler ultrasonography and CT angiography |